Get the Stockscreener App
25.88
0.54%
0.14
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.88, with a volume of 32.12M.
It is up +0.54% in the last 24 hours and up +2.94% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.74
Open:
$25.9
24h Volume:
32.12M
Relative Volume:
0.81
Market Cap:
$147.14B
Revenue:
$63.83B
Net Income/Loss:
$10.77B
P/E Ratio:
13.77
EPS:
1.88
Net Cash Flow:
$12.44B
1W Performance:
+2.94%
1M Performance:
+2.94%
6M Performance:
-1.60%
1Y Performance:
-10.08%
1-Day Range:
$25.76
$26.11
1-Week Range:
$25.01
$26.11
52-Week Range:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.88 | 142.54B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
How Much Would It Take To Earn $100 A Month From Pfizer Stock - Yahoo Finance
Pfizer Rises 0.24% Amid Legal and Clinical Setbacks, Trading Volume Ranks 92nd - AInvest
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire Inc.
Enanta files patent suit against Pfizer in Europe - Endpoints News
Pfizer battles another Paxlovid lawsuit from Enanta - Yahoo Finance
Myositis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare, Genentech - Barchart.com
Pfizer’s Latest Study on NSCLC Treatment: A Potential Game-Changer? - TipRanks
Pfizer sued by Enanta in EU patent fight (ENTA:NASDAQ) - Seeking Alpha
Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement - TipRanks
Enanta files patent infringement suit against Pfizer over Paxlovid - Investing.com
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union - FinancialContent
Stock Analysis | Pfizer OutlookMixed Signals Amid Volatile Market Dynamics - AInvest
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Pfizer’s (PFE) Oncology Gamble is Finally Paying Off - TipRanks
Pfizer says Canada just approved its new COVID-19 vaccine for this fall - Global News
Pfizer, Astellas Beat Challenge To Prostate Cancer Drug Patent - Law360
Pfizer Oncology Drugs Drive Sales In Q2: Will The Trend Continue? - Barchart.com
Pfizer Inc. Stock (PFE) Opinions on Recent Clinical Trial Results - Quiver Quantitative
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue? - Yahoo Finance
Pfizer Canada and HPIC Mark 30 Years of Humanitarian Partnership Delivering Global Health Impact - Seeking Alpha
Analyst recommendations: Arista Networks, Caterpillar, Pfizer, Broadcom, Nvidia… - MarketScreener
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True? - Yahoo Finance
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine - BioSpace
Lobbying Update: $3,710,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer/BioNTech updated COVID vaccine authorized in Canada - Seeking Alpha
Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag - insights.citeline.com
Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio - Oncodaily
Pfizer price surrounded with positive pressuresForecast today18-08-2025 - Economies.com
Pfizer’s sickle cell disease candidate fails Phase III trial - Yahoo Finance
Pfizer sickle cell hopes dim as inclacumab fails in late-stage trial - The Pharma Letter
Pfizer suffers another hit to its GBT sickle cell portfolio - pharmaphorum
Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment - Yahoo Finance
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer's Value Re-rating: Can Strong Institutional Interest and a Revitalized R&D Pipeline Justify a Buy? - AInvest
Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating - MSN
Pfizer Inc. - Britannica
Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given... - Medical Dialogues
Pfizer's Sickle Cell Drug Fails to Meet Main Goal, Safety Profile Remains a Potential Asset - AInvest
Can Pfizer Inc. maintain its current growth rateJuly 2025 Macro Moves & Intraday High Probability Setup Alerts - thegnnews.com
Is Pfizer's Turnaround Real, and Is the 6.5% Dividend Safe? - AInvest
Pfizer: This Is What Bulls Waited For - Seeking Alpha
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - MSN
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis Treatment - MSN
Pfizer and AbbVie Advance Pediatric Antibiotic Study: Market Implications - MSN
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings - MSN
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer? - MSN
Pfizer’s Tukysa Study: A Closer Look at Its Korean Market Impact - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer’s Talzenna®: New Korea PMS Study Update and Market Insights - TipRanks
Pfizer’s Promising Migraine Study: A New Hope for Adolescents - TipRanks
A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions - insights.citeline.com
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):